Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-01-2016 | Retinal Disorders

Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab

Authors: Ying Zhou, Yanrong Jiang, Yujing Bai, Jing Wen, Li Chen

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 1/2016

Abstract

Purpose

To evaluate vascular endothelial growth factor (VEGF) plasma levels before and after intravitreal injection of ranibizumab in patients with retinopathy of prematurity (ROP).

Methods

Case series study. Eleven infants with type 1 pre-threshold ROP were treated with intravitreal ranibizumab 0.5 mg. Blood samples were collected before intravitreal injection of ranibizumab and 1 day, 1 week, 2 weeks, and 4 weeks after injection. Concentration of plasma VEGF was measured by enzyme-linked immunosorbent assays (ELISA).

Results

The mean ± standard deviation of plasma VEGF concentration of the available samples before and 1 day, 1 week, 2 weeks, and 4 weeks after a total of 0.5 mg ranibizumab injection were 46.07 ± 9.40 pg/ml (n = 11), 10.59 ± 7.32 pg/ml (n = 5), 45.76 ± 6.75 pg/ml (n = 5), 62.44 ± 15.51 pg/ml (n = 5), and 56.82 ± 12.78 pg/ml (n = 4) respectively. A significant reduction was found in the plasma VEGF levels 1 day after intravitreal injection of ranibizumab (P = 0.002). No significant differences were found between before and 1 week, 2 weeks, and 4 weeks after the injection.

Conclusions

Intravitreal ranibizumab reduced plasma VEGF levels 1 day after injection in infants with ROP. This effect disappeared 1 week after the injection. Intravitreal ranibizumab did not induce prolonged systemic VEGF suppression.

Chen Y, Li XX (2006) Characteristics of severe retinopathy of prematurity patients in China: a repeat of the first epidemic? Br J Ophthalmol 90:268–271PubMedPubMedCentralCrossRef

Gilbert C (2008) Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 84:77–82PubMedCrossRef

Hartnett ME, Penn JS (2012) Mechanisms and management of retinopathy of prematurity. New Engl J Med 367:2515–2526PubMedPubMedCentralCrossRef

Fierson WM, American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists (2013) Screening examination of premature infants for retinopathy of prematurity. Pediatrics 131:189–195PubMedCrossRef

Vinekar A, Trese MT, Capone A Jr, Photographic Screening for Retinopathy of Prematurity Cooperative Group (2008) Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach. Am J Ophthalmol 145:548–555PubMedCrossRef

Early Treatment for Retinopathy of Prematurity Cooperative Group, Good WV, Hardy RJ et al (2010) Final visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol 128:663–671CrossRef

Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group B-RC (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New Engl J Med 364:603–615CrossRef

Castellanos MA, Schwartz S, Garcia-Aguirre G, Quiroz-Mercado H (2013) Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 97:816–819PubMedCrossRef

Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR (2015) Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. doi:10.1016/j.ophtha.2014.12.017

10.

Sato T, Wada K, Arahori H et al (2012) Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153(327–333):e321

11.

Ma Y, Zhang Y, Zhao T, Jiang YR (2012) Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab. Am J Ophthalmol 153(307–313):e2PubMed

12.

Hoerster R, Muether P, Dahlke C et al (2013) Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol 91:e74–e75PubMedCrossRef

13.

Mota A, Carneiro A, Breda J et al (2012) Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep Ophthalmol 3:136–141PubMedPubMedCentralCrossRef

14.

International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991–999CrossRef

15.

Gu X, Yu X, Dai H (2014) Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration. Curr Eye Res 39:518–521PubMedCrossRef

16.

Gaudreault J, Fei D, Beyer JC et al (2007) Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 27:1260–1266PubMedCrossRef

17.

Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V (2005) Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46:726–733PubMedCrossRef

18.

Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179–2182PubMedCrossRef

19.

Krohne TU, Liu Z, Holz FG, Meyer CH (2012) Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 154(682–686):e682CrossRef

20.

Xu L, Lu T, Tuomi L et al (2013) Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 54:1616–1624PubMedCrossRef

21.

Lowe J, Araujo J, Yang J et al (2007) Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 85:425–430PubMedCrossRef

22.

Banks RE, Forbes MA, Kinsey SE et al (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significant for VEGF measurements ans cancer biology. Br J Cancer 77(6):956–64PubMedPubMedCentralCrossRef

23.

Krohne TU, Eter N, Holz FG, Meyer CH (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146:508–512PubMedCrossRef

24.

Avery RL, Castellarin AA, Steinle NC et al (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98(12):1636–1641. doi:10.1136/bjophthalmol-305252 PubMedPubMedCentralCrossRef

25.

Investigators IS, Chakravarthy U, Harding SP et al (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399–1411CrossRef

26.

Carneiro AM, Costa R, Falcao MS et al (2012) Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 90:e25–e30PubMedCrossRef

27.

Kodjikian L, Souied EH, Mimoun G et al (2013) Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 120:2300–2309PubMedCrossRef

28.

Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN (2013) An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol 155(150–158):e151

Title: Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab
Authors: Ying Zhou
Yanrong Jiang
Yujing Bai
Jing Wen
Li Chen
Publication date: 01-01-2016
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 1/2016
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-015-2996-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Cholesterol granuloma: a case series & review of literature

In-vivo mapping of drusen by fundus autofluorescence and spectral-domain optical coherence tomography imaging

A biomimetic collagen/heparin multi-layered porous hydroxyapatite orbital implant for in vivo vascularization studies on the chicken chorioallantoic membrane

Effect of posterior vitreous detachment on aqueous humor level of vascular endothelial growth factor in exudative age-related macular degeneration patients

S100A4 gene silencing in oxygen-induced ischemic retinopathy inhibits retinal neovascularization via down-regulation of CREB expression

Science and art in retinopathy of prematurity diagnosis